Amgen Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 90,586,000,000.00 | ROE | 9.56 % |
| Balance Sheet | Total Equity | 8,658,000,000.00 | ROA | 8.51 % |
| Cashflow | Capital Expenditures | -1,858,000,000.00 | P/FCF | 28.51 |
| Cashflow | Free Cash Flow | 8,099,999,744.00 | – | – |
| Cashflow | Operating Cash Flow | 9,958,000,000.00 | P/CF | 23.19 |
| Income | Earnings per Share (diluted) | 14.23 | Div. Yield | 2.23 % |
| Income | Net Income | 7,711,000,000.00 | P/E | 29.94 |
| Income | Shares Outstanding | 538,800,000.00 | P/B | 26.67 |
| Income | Total Revenue | 36,751,000,000.00 | P/S | 6.28 |
Ratios calculated on: 10/14/2026
Company Description
Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In September 2013, Swedish Orphan Biovitrum AB (publ) (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen Inc for all therapeutic indications.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.amgen.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more